众议院能源与商务委员会的民主党高层周四要求疾病控制与预防中心（CDC）就该机构资助几内亚比绍一项有争议的乙肝临床试验一事作出解释。
Top Democrats on the House Energy and Commerce Committee on Thursday demanded answers from the Centers for Disease Control and Prevention (CDC) about the agency’s funding of a controversial hepatitis B clinical trial in Guinea-Bissau.
CDC去年向丹麦研究人员拨款160万美元，在几内亚比绍开展这项研究。这个西非小国近五分之一的人口感染了乙肝病毒，且不在出生时接种乙肝疫苗。该国计划到2028年实施出生剂次接种。
The CDC awarded $1.6 million last year to Danish researchers to conduct the study in Guinea-Bissau, a small country in West Africa where nearly one in five people are infected with the hepatitis B virus and which doesn’t vaccinate against hepatitis B at birth. The country plans to institute the birth dose by 2028.
据该研究的首席研究员称，这项本应测试出生时接种乙肝疫苗的长期效果的试验不会继续进行，因为它“未获得必要的政府批准”以推进。
The trial, which would have tested the long-term effects of receiving the hepatitis B vaccination at birth, is not going forward, according to its lead researcher, because it was “not given the necessary governmental approval” to proceed.
领导该研究的丹麦研究人员计划在临床试验中随机让1.4万名新生儿中的一半在出生时接种疫苗，许多其他科学家谴责这一做法极不道德且带有殖民主义色彩，因为这样的试验在美国不会获批。
The Danish researchers leading the study planned to randomly assign only half of the 14,000 newborns in the clinical trial to receive the vaccine at birth, a move that many other scientists decried as highly unethical and colonialist, since such a trial would not be approved in the U.S.
他们还质疑开展这项研究的必要性，鉴于乙肝疫苗研究已非常充分，且自美国医生开始在出生时接种该疫苗以来，该疾病已几近被消除。
They also questioned the need for a study in the first place, given how well researched the hepatitis B vaccine is and how successful it has been in practically eliminating the disease since doctors began administering it at birth in the U.S.
在致CDC主任埃里卡·施瓦茨的信中，民主党人谴责CDC似乎匆忙批准了该研究的资助——且资金来自全球卫生安全项目——而CDC却开始收缩其全球卫生版图。议员们要求在11月6日前进行工作人员级别的简报。
In a letter to CDC Director Erica Schwartz, the Democrats decried CDC’s decision to seemingly rush through funding for the study — and taking money from global health security — while it starts to shutter its global health footprint. The lawmakers asked for a staff level briefing by Nov. 6.
“这项拟议研究会伤害儿童，CDC不应批准用美国纳税人的钱为其提供资助，”卫生委员会首席议员弗兰克·帕洛内（民主党-新泽西州）、卫生小组委员会首席议员戴安娜·德盖特（民主党-科罗拉多州）以及监督与调查小组委员会首席议员伊薇特·克拉克（民主党-纽约州）写道。
“This proposed study harms children, and CDC should not have approved using American taxpayer dollars to fund it,” wrote Health Committee ranking member Frank Pallone, Jr. (D-N.J.), Health Subcommittee ranking member Diana DeGette (D-Colo.), and Oversight and Investigations Subcommittee ranking member Yvette D. Clarke (D-N.Y.).
世界卫生组织（WHO）建议给新生儿接种乙肝疫苗出生剂次，直到最近，美国疾病控制与预防中心（CDC）也持同样建议。
The World Health Organization (WHO) advises giving a birth dose of the hepatitis B vaccine, and until recently, so did the CDC.
今年早些时候，由卫生与公众服务部部长小罗伯特·F·肯尼迪精心挑选的一个联邦咨询小组投票决定，不再建议所有新生儿接种该疫苗，但这一举措被波士顿的一名法官叫停，作为一起正在进行的诉讼的一部分。肯尼迪及其盟友对乙肝疫苗的安全性表示怀疑。
Earlier this year, a federal advisory panel handpicked by Health Secretary Robert F. Kennedy Jr. voted to stop recommending the shot to all newborns, but that move was halted by a Boston judge as part of an ongoing lawsuit. Kennedy and his allies have cast doubt on the safety of the hepatitis B vaccine.
“CDC似乎在继续向国会和公众隐瞒关于该研究的设计、授予流程、伦理审查和资金来源等关键信息的同时，仍向该项目拨付资金，”这些议员写道。
“CDC appears to have allocated funding to this project even as it continues to withhold essential information from Congress and the public about the study’s design, award process, ethical review, and financing,” the lawmakers wrote.
该试验于2025年12月首次宣布，但遭到了国会议员以及国际和公共卫生界的强烈抨击。
The trial was first announced in December 2025 but was met with severe backlash by members of Congress, as well as the international and public health community.
几内亚比绍外长表示该研究已被终止，但民主党议员称，“看来CDC仍在推进资助一项会让儿童陷入不必要的痛苦、器官衰竭甚至死亡的研究。”议员们要求特朗普政府保证不会再次尝试，无论是同一项研究还是类似的研究。
Guinea-Bissau’s foreign minister said the study had been terminated, but the Democrats said, “it appears that CDC was still forging ahead by funding a study that dooms children to needless suffering, organ failure, or even death.”The lawmakers demanded assurances the Trump administration wouldn’t try again, with either the same study or a similar one.